Neuren Pharmaceuticals Limited (NURPF) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neuren Pharmaceuticals Ltd. (NURPF) has launched a Phase 3 open-label extension study called “A Phase 3 Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Orally Administered NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome.” The goal is to track long-term safety and benefit in children with this rare neurodevelopmental condition and support future regulatory decisions.
The treatment is NNZ-2591, an oral drug taken twice a day. It is designed to improve symptoms linked to Phelan-McDermid syndrome over extended use and could become a first-in-class option if late-stage data are strong.
The trial is interventional and uses a single treatment group, so every child receives NNZ-2591 instead of a placebo. There is no blinding, and the main goal is treatment, making the design simple to run but more focused on safety and durability of effect than on strict comparison.
The study was first submitted on March 24, 2026, marking the formal start of the long-term program. The last update was filed on May 20, 2026, showing that recruitment is active and the protocol is current, with primary and final completion timing to be confirmed as enrollment progresses.
For investors, this update signals that Neuren is pushing NNZ-2591 deeper into late-stage development, adding another orphan neurology asset alongside its existing portfolio. Progress in a Phase 3 extension can lift sentiment and valuation, though the rare-disease focus and lack of placebo control mean that regulators and investors will watch real-world outcomes and competitor moves in pediatric neurology closely.
The NNZ-2591 Phase 3 extension in Phelan-McDermid syndrome is ongoing and recently updated, with more details available on the ClinicalTrials.gov portal.
To learn more about NURPF’s potential, visit the Neuren Pharmaceuticals Limited drug pipeline page.